Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357794 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
A Phase 2 study of Mycosis Fungoides, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05357794 is a Phase 2 study of Mycosis Fungoides that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05357794, a Phase 2 study of Mycosis Fungoides, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides
Conditions Studied
Interventions
- DRUG Brentuximab vedotin
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-10-13 |
| Est. Completion | 2027-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05357794
The ClinicalTrials.gov registry entry for NCT05357794 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 162-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (81% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mycosis Fungoides appearing as the primary indexed condition, and to 1 intervention - of which Brentuximab vedotin is the first listed.
NCT05357794 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05357794 about?
NCT05357794 is a clinical study titled "Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides". To learn if a form of radiation therapy (called ultra-low-dose - total skin electron beam therapy \[ULD-TSEBT\]) in combination with brentuximab vedotin can help to control mycosis fungoides
What is the current status of trial NCT05357794?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-10-13. Estimated completion is 2027-01-30.
What conditions does trial NCT05357794 study?
This clinical trial studies the following conditions: Mycosis Fungoides.
What interventions are being tested in trial NCT05357794?
The interventions under investigation include: Brentuximab vedotin (DRUG).
Who is sponsoring clinical trial NCT05357794?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357794 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
ACTIVE NOT RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.